[vc_row css_animation= » » row_type= »row » use_row_as_full_screen_section= »no » type= »grid » angled_section= »no » text_align= »left » background_image_as_pattern= »without_pattern » css= ».vc_custom_1501252135023{margin-top: -96px !important;background-color: #679fdd !important;} »][vc_column][vc_column_text]
[flexy_breadcrumb]
[/vc_column_text][/vc_column][/vc_row][vc_row css_animation= » » row_type= »row » use_row_as_full_screen_section= »no » type= »grid » angled_section= »no » text_align= »left » background_image_as_pattern= »without_pattern » css= ».vc_custom_1501252153676{padding-top: 90px !important;} »][vc_column][vc_column_text]
VISIOMED GROUP (FR0011067669 – ALVMG), a company specializing in new generation medical electronics, is pleased to announce the registration with the Food and Drug Administration (FDA) of MyOxy®, the web-enabled pulse oximeter, and MyECG®, the web-enabled electrocardiogram, which was presented with an Innovation Award in the Biotech category at CES 2016.
[/vc_column_text][/vc_column][/vc_row][vc_row css_animation= » » row_type= »row » use_row_as_full_screen_section= »no » type= »full_width » angled_section= »no » text_align= »left » background_image_as_pattern= »without_pattern » css= ».vc_custom_1501252181948{padding-bottom: 140px !important;} »][vc_column][vc_row_inner row_type= »row » type= »full_width » text_align= »left » css_animation= » » css= ».vc_custom_1501252192119{padding-top: 50px !important;} »][vc_column_inner width= »1/3″][/vc_column_inner][vc_column_inner width= »1/3″][vc_column_text]
[/vc_column_text][vc_empty_space height= »20px »][vc_column_text]
Back to the press release list
[/vc_column_text][/vc_column_inner][vc_column_inner width= »1/3″][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row]